Browse > Article
http://dx.doi.org/10.4046/trd.2010.69.4.293

Bronchiolitis Obliterans Organizing Pneumonia in the Patient with Non-Small Cell Lung Cancer Treated with Docetaxel/Cisplatin Chemotherapy: A Case Report  

Kim, Ae-Ran (Department of Internal Medicine, Daedong Hospital)
Kim, Tae-Young (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Pusan Paik Hospital, Inje University College of Medicine)
Lee, Young-Min (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Pusan Paik Hospital, Inje University College of Medicine)
Lee, Seung-Heon (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Pusan Paik Hospital, Inje University College of Medicine)
Jung, Soo-Jin (Department of Pathology, Pusan Paik Hospital, Inje University College of Medicine)
Lee, Hyun-Kyung (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Pusan Paik Hospital, Inje University College of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.69, no.4, 2010 , pp. 293-297 More about this Journal
Abstract
A 60-year-old man was diagnosed with stage IV squamous cell carcinoma of lung and treated with weekly doses of docetaxel and cisplatin. Tumor mass and mediastinal lymphadenopathy disappeared after 4.5 cycles of chemotherapy. At one week post final chemotherapy, the patients developed sudden shortness of breath. New, multifocal infiltrations developed on both lungs without definitive evidence of infection. Despite administration of broad spectrum antibiotics, the lung lesion did not improve, so bronchoalveolar lavage and computed tomography-guided lung biopsy were performed. The proportion of lymphocytes was increased markedly and histopathology revealed squamous cell carcinoma combined with bronchiolitis obliterans organizing pneumonia. After high dose corticosteroid therapy, dyspnea and the newly developed consolidation had decreased slightly. However, dyspnea and hypoxemia increased again because of aggravated lung cancer since chemotherapy had stopped. Chemotherapy couldn't be restarted due to the poor performance status of the patient. Later, patient died of respiratory failure from poor general condition and progression of lung cancer.
Keywords
Cryptogenic Organizing Pneumonia; Docetaxel; Lung Neoplasms; Drug Therapy;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Lazor R, Vandevenne A, Pelletier A, Leclerc P, Court- Fortune I, Cordier JF. Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. The Groupe d'Etudes et de Recherche sur les Maladles "Orphelines" Pulmonaires (GERM"O"P). Am J Respir Crit Care Med 2000;162:571-7.   DOI
2 Veltkamp SA, Meerum Terwogt JM, van den Heuvel MM, van Boven HH, Schellens JH, Rodenhuis S. Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel. Invest New Drugs 2007;25:279-81.   DOI   ScienceOn
3 Epler GR, Colby TV, McLoud TC, Carrington CB, Gaensler EA. Bronchiolitis obliterans organizing pneumonia. N Engl J Med 1985;312:152-8.   DOI   ScienceOn
4 Santrach PJ, Askin FB, Wells RJ, Azizkhan RG, Merten DF. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer 1989;64:806-11.   DOI   ScienceOn
5 Jacobs C, Slade M, Lavery B. Doxorubicin and BOOP. A possible near fatal association. Clin Oncol (R Coll Radiol) 2002;14:262.   DOI   ScienceOn
6 Kouroussis C, Mavroudis D, Kakolyris S, Voloudaki A, Kalbakis K, Souglakos J, et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung cancer 2004;44:363-8.   DOI   ScienceOn
7 Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 2006;129:1031-8.   DOI   ScienceOn
8 Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002;94:847-53.   DOI   ScienceOn
9 Onishi H, Kuriyama K, Yamaguchi M, Komiyama T, Tanaka S, Araki T, et al. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung cancer 2003;40:79-84.   DOI   ScienceOn
10 Dunsford ML, Mead GM, Bateman AC, Cook T, Tung K. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 1999;10: 943-7.   DOI   ScienceOn
11 Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997;80:286-91.   DOI   ScienceOn
12 Merad M, Le Cesne A, Baldeyrou P, Mesurolle B, Le Chevalier T. Docetaxel and interstitial pulmonary injury. Ann Oncol 1997;8:191-4.   DOI   ScienceOn
13 Ravdin PM, Burris HA 3rd, Cook G, Eisenberg P, Kane M, Bierman WA, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedioneresistant breast cancer. J Clin Oncol 1995;13:2879-85.
14 Takeda K, Negoro S, Tamura T, Nishiwaki Y, Kudoh S, Yokota S, et al. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol 2009; 20:835-41.   DOI   ScienceOn
15 Taxane-induced pulmonary toxicity. UpToDate version 14.3. [Internet]. Waltham: UpToDate Inc.; c2010 [cited 2010 Oct 8]. Available from: http://www.uptodate.com.